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Brain metastases are life-threatening complications of triple-negative breast
cancer, melanoma, and a few other tumor types. Poor outcome of cerebral
secondary tumors largely depends on the microenvironment formed by
cells of the neurovascular unit, among which pericytes are the least charac-
terized. By using in vivo and in vitro techniques and human samples, here
we show that pericytes play crucial role in the development of metastatic
brain tumors by directly influencing key steps of the development of the
disease. Brain pericytes had a prompt chemoattractant effect on breast can-
cer cells and established direct contacts with them. By secreting high
amounts of extracellular matrix proteins, pericytes enhanced adhesion of
both melanoma and triple-negative cancer cells, which might be particu-
larly important in the exclusive perivascular growth of these tumor cells. In
addition, pericytes secreted insulin-like growth factor 2 (IGF2), which had
a very significant pro-proliferative effect on mammary carcinoma, but not
on melanoma cells. By inhibiting IGF2 signaling using silencing or picrop-
odophyllin (PPP), we could block the proliferation-increasing effect of peri-
cytes on breast cancer cells. Administration of PPP (a blood–brain barrier-
permeable substance) significantly decreased the size of brain tumors in
mice inoculated with triple-negative breast cancer cells. Taken together,
our results indicate that brain pericytes have significant pro-metastatic fea-
tures, especially in breast cancer. Our study underlines the importance of
targeting pericytes and the IGF axis as potential strategies in brain meta-
static diseases.
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1. Introduction
Cerebral metastases are frequent and dismal complica-
tions of a few tumor cell types, including lung cancer,
breast cancer, and melanoma. In breast cancer, which
is the second most frequent cause of central nervous
system (CNS) metastases, brain lesions primarily occur
in triple-negative (estrogen receptor-, progesterone
receptor-, and Her2-negative) and Her2/neu-overex-
pressing subtypes. Triple-negative breast cancer
(TNBC) has a particularly poor prognosis, many
patients developing and eventually dying of brain
metastasis [1]. Melanoma, the third most common
brain metastatic tumor, represents the highest risk to
spread to the CNS, and brain metastases are a leading
cause of death from this disease [2].
Presence of the blood–brain barrier (BBB) [3], tumor
heterogeneity and plasticity [4], and unique molecular
features of brain metastatic cells [5] all contribute to
the poor outcome of cerebral secondary tumors. The
most important unique aspects of brain metastasis
development are linked to the neurovascular unit
(NVU), that is, cerebral endothelial cells (CECs), peri-
cytes, glial cells, and neurons, with whom tumor cells
form complex interactions [6]. These interactions have
been extensively studied, except for pericytes.
Brain pericytes are mural cells located in the dupli-
cation of the basement membrane of microvessels,
coming in close contact with cerebral endothelial and
glial cells. They may act as regulators of vessel forma-
tion and stabilization [7,8], BBB permeability [9,10]
and—although still debated—cerebral blood flow
[11,12]. Pericytes play a crucial role in various neuro-
logical diseases, including ischemia, traumatic injury,
neurodegenerative and neuro-immune conditions, and
also glioblastoma [13]. However, interactions of brain
pericytes with metastatic tumor cells are largely unex-
plored, although pericytes have recently emerged as
important players in creating the premetastatic niche
in peripheral organs [14]. Since microvessels of the
CNS have the highest pericyte coverage in the organ-
ism [15], we hypothesized that pericyte-metastatic cell
interactions might be particularly critical in the brain.
2. Materials and methods
2.1. Cell culture
2.1.1. Culture of human NVU cells
Human brain vascular pericytes (abbreviated as HBVP;
obtained from ScienCell Research Laboratories,
Carlsbad, CA, USA) were cultured on poly-L-lysine-
coated dishes in Pericyte Medium (PM; ScienCell
Research Laboratories) supplemented with 5% FBS
(Sigma-Aldrich, St. Louis, MO, USA) and penicillin/
streptomycin solution (P/S; ScienCell Research Labora-
tories) and used between passage numbers 2 and 6.
Human astrocytes (HA; ScienCell Research Laborato-
ries) were grown on poly-L-lysine-coated dishes in astro-
cyte medium (AM) supplemented with 5% FBS and P/S
(all from ScienCell Research Laboratories) and used
between passage numbers 2 and 4. Human microvascu-
lar cerebral endothelial cells (hCMEC/D3, shortly D3)
were cultured on rat-tail collagen-coated dishes in
endothelial cell basal medium-2 (EBM-2) with EGM-
2MV kit including supplements and 2% FBS (all from
Lonza, Basel, Switzerland) and used between passage
numbers 30 and 40.
2.1.2. Isolation and culture of mouse NVU cells
Venus-YFP-expressing primary mouse brain endothelial
cells were isolated from 6- to 8-week-old FVB/Ant:
TgCAG-yfp_sb #27 mice, as described previously [16].
Murine pericytes were collected in parallel with endothe-
lial cells after the first enzymatic digestion. Pericytes were
seeded onto rat-tail collagen-coated dishes and kept in
PM supplemented with 5% FBS (Sigma-Aldrich) and P/
S solution. Mouse pericytes were used for experiments
between passage numbers 5 and 7. Primary mouse astro-
cytes were isolated from brains of 1- to 3-day-old Balb/c
mouse pups by mechanical trituration. Astrocytes were
seeded onto poly-L-lysine-coated dishes and kept in low-
glucose Dulbecco’s modified Eagle’s medium (DMEM;
Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% FBS (Sigma-Aldrich).
2.1.3. Culture of tumor cells
MDA-MB-231 human triple-negative breast cancer cells
(shortly MDA), enhanced green fluorescent protein
(EGFP)-expressing MDA-MB-231 cells (shortly MDA-
EGFP); mouse triple-negative mammary carcinoma cells
4T1, 4T1-tdTomato and 4T1-EmGFP (expressing emer-
ald GFP); A2058 human and B16/F10 (abbreviated as
B16) murine melanoma cells were cultured as described
previously [17]. A2058-EGFP cells were obtained by
transfection with the pEGFP-C1 plasmid using Turbo-
Fect reagent (Thermo Fisher Scientific) and selection
with 500 lgmL1 G418 (Thermo Fisher Scientific).
All cell lines were regularly tested for mycoplasma
contamination using the MycoAlert Mycoplasma
Detection Kit (Lonza). Only mycoplasma-negative cul-
tures were used for experiments.
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2.2. Preparation of conditioned media
Human and mouse cells were grown until 90% conflu-
ency in 6-cm culture dishes. Growth medium was
replaced with HBVP complete medium (PM + 5%
FBS + P/S) and left for 2 days. Nonconditioned com-
plete medium was used as negative control. All media
were filtered through 0.2-µm pore size syringe filters to
remove cells and debris.
Extracellular vesicles (EVs) were depleted from HBVP
control and conditioned media by using a serial centrifu-
gation protocol: 700 g, 5 min; 1000 g, 8 min; 10 000 g,
30 min and 150 000 g, 90 min. Media were collected and
filtered through 0.1-µm pore size syringe filters.
2.3. Experimental animal surgeries
All mice were housed and treated in accordance with
widely accepted standards, and the protocols were
approved by the institutional care and the Regional
Animal Health and Food Control Station of Csongrad
County (permit number: XVI./764/2018). Surgeries
were carried out on 6- to 10-week-old female FVB/
Ant:TgCAG-yfp_sb #27 mice (obtained from Institute
of Experimental Medicine, Budapest, Hungary), as
described previously [16]. For ex vivo experiments, 6-
to 10-week-old female mice received 106 4T1-tdTomato
cells in 100 µL into the right common carotid artery.
For testing the effect of picropodophyllin (PPP) on
tumor growth in vivo, animals were inoculated with
3 9 106 4T1-tdTomato cells/200 µL by intracardiac
injection. The well-being of the animals was monitored
daily during the postoperative period. No infection or
wound dehiscence was detected, neither any signs of
chronic pain. Maximum 5% of weight loss was
observed, and the operation-induced mortality rate
was 2–3%. On days 5 and 6 postinjection, mice
received 40 mgkg1 PPP (Alfa Aesar, Thermo Fisher
Scientific) in corn oil or vehicle only, intraperitoneally.
On day 8, mice were transcardially perfused. Coronary
brain sections were prepared from all animals from
parietal cortical regions, and the same volumes were
used for imaging with a Leica SP5 microscope (Leica
Biosystems, Wetzlar, Germany). Tumor-covered areas
in control and PPP-treated animals were measured
with FIJI software using a custom-made macro [18].
2.4. Immunofluorescence
Human triple-negative breast cancer brain metastasis
and control brain samples were acquired from the
Department of Pathology, University of Szeged.
Human samples were collected in accordance with the
permission of the Human Investigation Review Board,
University of Szeged (permit number: EMLOSEB001,
issued on January 31, 2017), in agreement with the
Declaration of Helsinki of the World Medical Associa-
tion. Surgical samples were fixed in PFA and embed-
ded into paraffin blocks. Five-micrometer-thick slices
were used for immunofluorescence staining. After
deparaffinization in xylol, samples were rehydrated
through a descending series of alcohol to water. Anti-
gen retrieval was performed by boiling in 10 mM
sodium citrate pH = 6 for 15 min.
After fixation, whole mouse brains were mounted
onto a freezing microtome (Reichert-Jung, Leica
Biosystems) and 20-µm-thick coronal brain sections
were cut, which were kept in PBS with 0.05% sodium
azide until further processing. Antigen retrieval was
performed by incubating the sections at 80 °C for
30 min in 10 mM sodium citrate pH = 6.
All sections were permeabilized in 0.5% Triton X-
100 (Sigma-Aldrich) for 20 min, then blocked with 3%
BSA (VWR International, Radnor, PA, USA) in PBS
containing 0.5% Triton X-100 for 1 h. Primary anti-
bodies (Table S1) were diluted in 1% BSA with 0.5%
Triton X-100, and sections were incubated overnight
at 4 °C on an orbital shaker. Slides were extensively
washed in PBS. Alexa Fluor 488-labeled anti-rabbit,
Alexa Fluor 594-labeled anti-mouse, Alexa Fluor 647-
labeled anti-goat IgG (Thermo Fisher Scientific), and
STAR RED-labeled anti-rabbit IgG (Abberior,
G€ottingen, Germany) were used as secondary antibod-
ies in a dilution of 1 : 300 in PBS for 60 min at room
temperature in the dark. Sections were washed, coun-
terstained with a nuclear dye (Hoechst 33342; Sigma-
Aldrich) for 10 min, washed again with PBS, rinsed in
water, and mounted in FluoroMount-G (South-
ernBiotech, Birmingham, AL, USA).
Samples were analyzed using a Leica SP5 confocal
laser scanning microscope.
2.5. Adhesion experiments
2.5.1. Adhesion in co-culture
HBVP cells were stained with CellTrackerTM Red
CMTPX Dye (Thermo Fisher Scientific), extensively
washed, and mixed with MDA-EGFP cells in a ratio of
1 : 1. Mixed culture was seeded onto poly-L-lysine-coated
dishes in complete HBVP medium and left for 3 days.
2.5.2. Cell-to-cell adhesion
D3, HBVP, or HA cells were seeded into 12-well plates
(noncoated or coated with poly-L-lysine or rat-tail
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collagen) in a density of 2 9 104 cells/well. After 24 h,
1.5 9 104 cells/well MDA-EGFP or A2058-EGFP
were seeded onto the cells and incubated for 24 h.
Phase-contrast and fluorescence images were taken
with a Nikon Eclipse TE2000U (Nikon, Tokyo, Japan)
microscope connected to a digital camera (Spot RT
KE, Diagnostic Instruments, Sterling Heights, MI,
USA). Attached fluorescent cells were counted using
FIJI software [18].
2.5.3. Cell-to-surface adhesion
5 9 105 tumor cells were seeded into 6-well plates in
pericyte-conditioned or control media in the presence
or absence of Src inhibitors (Selleck Chemicals,
Munich, Germany) and left for 20 min (A2058, 4T1
and B16) or 120 min (MDA). Floating cells were col-
lected by centrifugation, and phase-contrast images
were taken from attached cells. Efficiency of cell adhe-
sion was determined by counting the adherent cells.
For further western blot analysis, attached and float-
ing cells were mixed together in radioimmunoprecipita-
tion assay buffer (RIPA).
In another setup, 6-well plates were pretreated with
endothelial cell-, pericyte-, or astrocyte-conditioned
media for 24 h. Conditioned media were removed, and
5 9 105 tumor cells were seeded into the pretreated
wells in control medium.
2.6. Migration assays
2.6.1. Short-distance migration assay (wound healing)
3 9 104 MDA cells and 1.5 9 104 HBVP or 3 9 104
D3 cells were seeded into rat-tail collagen-coated sili-
cone 3-well culture inserts (Ibidi, Graefelfing, Ger-
many). After reaching confluency, the insert was
removed and culture medium was changed to Lei-
bovitz’s L-15 medium (Sigma-Aldrich) supplemented
with 1% FBS. Migration of cells was monitored for
24 h in phase-contrast.
2.6.2. Long-distance migration assay
3 9 104 HBVP cells and 6 9 104 MDA-EGFP and D3
cells were seeded into every second well of a rat-tail
collagen-coated silicone 12-well culture insert (Ibidi).
After reaching confluency, the insert was removed.
After 5 days, phase-contrast and fluorescence images
were taken from the whole area and an overview
image was generated.
2.7. Proliferation assays
2.7.1. Phase-contrast imaging and cell number counting
104 tumor cells/well were plated into 6-well plates, and
fresh medium was given every other day. For cell
counting, phase-contrast images were taken every day.
After 4 days, cells were collected in RIPA buffer for
western blot analysis.
2.7.2. Real-time impedance monitoring
104 4T1 or B16/F10 cells were seeded into E-plates in
control or pericyte-conditioned medium with or with-
out 100 nM PPP. Fresh medium was provided after
48 h. Electrical impedance was measured in real-time
using the xCELLigence system (ACEA Biosciences,
San Diego, CA, USA).
2.8. Methanol–chloroform precipitation and
western blot
Conditioned media were centrifuged to seed cell debris,
and an equal volume of methanol and 1/4 volume of
chloroform were added. Samples were vortexed, incu-
bated for 5 min on ice, and centrifuged at 10 000 g for
5 min at 4 °C. After phase separation, aqueous phase
was removed and protein samples were washed with
ice-cold methanol. Samples were vortexed and cen-
trifuged again, supernatants were discarded, and pro-
tein pellets were air-dried. Pellets were reconstituted in
29 Laemmli buffer and heated up to 95 °C for 5 min.
Cells were lysed in RIPA buffer. Protein concen-
tration was determined by using bicinchoninic acid
assay (Thermo Fisher Scientific). Laemmli buffer was
added to the samples and incubated at 95 °C for
5 min. Samples were electrophoresed using standard
denaturing SDS/PAGE and blotted on polyvinylidene
difluoride (0.2 lm pore size; Bio-Rad, Hercules, CA,
USA, or 0.45 lm pore size; BioTrace, Pall Corpora-
tions, Port Washington, NY, USA) or nitrocellulose
membranes (0.2 lm pore size; Bio-Rad). After block-
ing with 3% BSA or 5% nonfat milk in Tris-buf-
fered saline with 0.1% Tween-20 (TBS-T),
membranes were incubated with primary antibodies
(Table S1) overnight at 4 °C. Blots were washed in
TBS-T three times for 10 min, incubated for 1 h in
horseradish peroxidase-conjugated anti-rabbit IgG or
anti-mouse IgG secondary antibodies (Jackson
ImmunoResearch, Cambridgeshire, UK) diluted to
1 : 3000 in TBS-T, and then washed again in TBS-T.
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Immunoreaction was visualized with Clarity Chemi-
luminescence Substrate (Bio-Rad) in a ChemiDoc
MP System (Bio-Rad). Densitometry analysis was
performed with the IMAGE LAB Software, version 5.2
(Bio-Rad).
2.9. RNA isolation and real-time polymerase
chain reaction
Total RNA was isolated using TRIfast reagent (VWR
International). Maxima First Strand cDNA Synthesis
Kit (Thermo Fisher Scientific) was used to transcribe
RNA into cDNA. Amplification was performed using
iTaqTM Universal SYBR Green Supermix (Bio-Rad)
or Luminaris Color HiGreen qPCR Master Mix kit
(Thermo Fisher Scientific) on a Bio-Rad iQ5 instru-
ment under the following conditions: 40 cycles of
95 °C for 15 s, 56–60 °C for 30 s, 72 °C for 30 s using
primers detailed in Table S2.
2.10. Enzyme-linked immunosorbent assay
After collection of conditioned media, cells were tryp-
sinized and counted in a hemocytometer. Conditioned
media were centrifuged at 1000 g for 15 min at 4 °C.
Insulin-like growth factor 1 (IGF1) and IGF2 contents
of conditioned media were measured using commercial
ELISA kits (CSB-E04580h and CSB-E04583h, respec-
tively; Cusabio, Wuhan, China) following the manu-
facturer’s instructions.
2.11. Silencing of Igf2 gene
StealthTM siRNA duplex oligoribonucleotides were
designed using Invitrogen BLOCK-iTTM RNAi designer
and purchased from Thermo Fisher Scientific. The
following sequences were used: sense, 50-UCGAUG-
CUGGUGCUUCUCACCUUCU-30 and antisense,
50-AGAAGGUGAGAAGCACCAGCAUCGA-30. Cell
transfection was performed with Lipofectamine 2000, as
previously described [19].
2.12. Statistical analysis
Student’s t-test and analysis of variance (ANOVA)
were performed using the Excel 2016 Data Analysis
plugin. For post hoc tests, we applied SIGMAPLOT ver-
sion 12.3 (Systat Software Inc., Chicago, IL, USA).
3. Results
3.1. Direct interaction of brain metastatic tumor
cells with pericytes in vivo and in vitro
We have previously shown that TNBC cells proliferate
along capillaries in the mouse brain, co-opting the
endothelium, but expelling astrocytes and astrocyte
end-feet to the surface of the tumor [16]. Since tumor
co-opted endothelial cells maintained tight junctions in
the absence of astrocyte end-foot coverage, we investi-
gated whether pericytes—another cell type involved in
the induction of barrier properties of CECs [9,10]—re-
mained in contact with the vessels, as previously
described in a different metastatic model [20]. Indeed,
we found that PDGFRb (platelet-derived growth fac-
tor receptor b)-positive pericytes were localized to cap-
illaries inside metastatic lesions in the mouse brain
(Fig. 1A). In human TNBC brain metastases,
PDGFRb-positive perivascular cells were found in the
stroma (Fig. 1B), in single or multiple layers, as previ-
ously shown [21]. In addition, we have also detected
single pericyte-like cells expressing the specific markers
PDGFRb and CD13, scattered among the tumor cells,
especially in less cell-dense areas, probably in the prox-
imity of necrotic zones (Fig. 1C).
All these data prompted us to hypothesize that
direct interactions between tumor cells and pericytes
might influence brain metastasis development. There-
fore, we first modeled contacts between metastatic cells
and pericytes using an in vitro setup, by plating the
tumor cells onto sparse cultures of brain pericytes and
other cells of the NVU. Breast cancer cells
Fig. 1. Direct interactions of pericytes with tumor cells. (A) Brain sections of FVB/Ant:TgCAG-yfp mice 11 days after injection of 4T1-
tdTomato cells showing PDGFRb-positive pericytes localized along capillaries inside the tumor mass. Scale bars = 10 µm. (B) Human triple-
negative brain metastatic tissue with PDGFRb-positive pericytes in the stroma. Scale bar = 10 µm. (C) Human triple-negative brain
metastatic tissue with PDGFRb (red) and CD13 (green) double-positive (yellow) pericyte-like cells scattered among tumor cells. Scale
bar = 10 µm. (D) Co-culture of CellTrackerTM Red-stained human pericytes (HBVP cells) and human triple-negative breast cancer (MDA-EGFP)
cells 3 days after seeding. Scale bar = 100 µm. (E) Quantification of tumor cell adhesion 24 h after seeding onto brain cells cultured in poly-
L-lysine-coated dishes. Breast cancer cells: MDA-EGFP, melanoma cells: A2058-EGFP, endothelial cells: D3, pericytes: HBVP, astrocytes:
HA. N = 5, average  SD, **P < 0.01 (ANOVA and Bonferroni’s post hoc test). (F) Comparison of human breast cancer cell (MDA-EGFP)
adhesion to D3 and HBVP cells. N = 3, average  SD, **P < 0.01 (ANOVA and Bonferroni’s post hoc test).
2045Molecular Oncology 14 (2020) 2040–2057 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
K. Molnar et al. Pericytes promote brain metastasis formation
preferentially gathered onto the top of pericytes,
avoiding the cell-free culture surface (Fig. 1D,E), and
this was independent of the coating of the culture dish
(Fig. 1F). In contrast, when breast cancer cells were
co-cultured with CECs, they seldom adhered onto
endothelial cells, but rather into gaps among them. In
co-culture with astrocytes, direct contacts of the tumor
cells were more frequent than with endothelial cells,
Fig. 2. Migration of breast cancer cells toward brain pericytes. (A) Representative phase-contrast images of pericyte-breast cancer cell and
brain endothelial-breast cancer cell migration (short-distance invasion assay—described in Materials and methods). Scale bar = 100 µm. (B)
Quantitative analysis of the short-distance wound assays at 24 h. N = 5, average  SD, **P < 0.01 (Student’s t-test). (C) Phase-contrast
and fluorescence (green insets) images of HBVP, D3, and MDA-EGFP cells after 5 days of migration in the long-distance invasion assay.
Scale bars = 1 mm (top panels) and 100 µm (bottom panels).
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but less preferred than interaction with pericytes
(Fig. 1E, Fig. S1). In contrast to breast cancer cells,
the highest number of melanoma cells attached to free
surfaces among the cells, independent of the cell type
they were co-cultured with (Fig. 1E, Fig. S1).
As a next step, we aimed to explore whether breast
cancer cells could actively migrate in the direction of
brain pericytes. Carcinoma cells readily migrated
toward pericytes, covering a significantly larger distance
on their way to brain pericytes than to endothelial cells
(Fig. 2A,B). When leaving a much longer distance
(more than 1 cm) between tumor cells and two different
brain cells (endothelial cells and pericytes, respectively),
breast carcinoma cells preferentially migrated in the
direction of pericytes. After a few days, several breast
cancer cells were detected in the initially cell-free area
between tumor cells and pericytes and large breast can-
cer cell colonies were formed among pericytes. On the
other hand, only a few scattered mammary carcinoma
cells were observed in the direction of and among
endothelial cells (Fig. 2C). These results indicate that
pericytes might communicate with tumor cells through
secreted factors. Therefore, we conditioned culture med-
ium on brain pericytes to characterize in details its
effects on neoplastic cells.
3.2. Effects of pericytes on tumor cell adhesion
First, we seeded breast cancer and melanoma cells in con-
trol and pericyte-conditioned media and performed an
adhesion assay. As shown in Fig. 3A–D, both human
and mouse breast cancer and also melanoma cells
attached to the culture dish surface and elongated more
rapidly in pericyte-conditioned media, than in control
conditions. The difference between cells seeded in control
and conditioned media was very high and significant
(Fig. 3C,D). Next, prior to seeding of the tumor cells, we
pretreated the culture dishes with conditioned media of
brain pericytes, endothelial cells, or astrocytes and per-
formed an adhesion assay. Pericyte-conditioned medium
enhanced attachment of both breast cancer and mela-
noma cells more effectively than endothelial-derived med-
ium, while astrocyte-secreted factors had a more
pronounced effect on breast cancer cells and were less
effective on the adhesion of melanoma cells (Fig. 3E).
Adhesive substrate for the cells is provided by extra-
cellular matrix, for example, basement membrane pro-
teins. Therefore, we tested secretion of type IV
collagen and fibronectin, two major components of the
vascular basal lamina in the brain. According to our
data, pericytes—similar to astrocytes—secreted high
amounts of collagen type IV and fibronectin (Fig. 3F,
G). These results explain the prominent adhesion
enhancing effect of pericytes and astrocytes.
Cells attach to the extracellular matrix in focal adhe-
sions, which are regulated by FAK (focal adhesion
kinase), Src, and other signaling proteins [22]. Both
FAK and Src phosphorylation increased in breast can-
cer and melanoma cells seeded in pericyte-conditioned
media (Fig. S2A,B). In addition, PP2, a specific Src
inhibitor—but not the structurally related negative
control PP3—significantly reduced the adhesion-induc-
ing effect of pericyte-conditioned media (Fig. S2C–E).
3.3. Effects of pericytes on tumor cell
proliferation
As a next step, we aimed to understand how brain peri-
cytes influence tumor growth. Therefore, we performed a
tumor cell proliferation assay in the presence and
absence of factors released by pericytes. Four days after
plating, the number of breast cancer cells was substan-
tially higher in pericyte-conditioned than in control
media (Fig. 4A,B). This was clearly observed both in the
human and in the mouse model. On the other hand, mel-
anoma cells did not respond with increased proliferation
to the presence of pericyte-secreted factors (Fig. 4A and
Fig. S3A). In parallel, there was a significant increase in
the expression of cyclin D1 in human and mouse breast
cancer cells, but not in melanoma cells cultured in peri-
cyte-conditioned media (Fig. 4C,D).
Besides soluble factors, conditioned media may con-
tain EVs, like microvesicles and exosomes. In order to
distinguish between effects of EVs and soluble factors,
we prepared EV-depleted conditioned medium and
compared it with complete conditioned medium in a
proliferation assay. EV depletion did not influence the
proliferation-increasing effect of pericyte-conditioned
medium (Fig. 4E); therefore, soluble factors released
by pericytes are responsible for the observed phe-
nomenon.
Interestingly, breast cancer cells in the conditioned
media, although higher in number, appeared to have
fewer contact points with each other and became more
dissociated (Fig. 4F). In line with this, E-cadherin
expression decreased significantly in breast cancer cells
being exposed to pericyte-secreted factors (Fig. 4G,H).
3.4. Insulin-like growth factor expression in
cerebral pericytes
In order to identify which cerebral pericyte-secreted
factors might be involved in enhancing tumor cell
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proliferation, we first performed a database search. In
the http://betsholtzlab.org/VascularSingleCells/databa
se.html collection [23], we found Igf2 mRNA having
the highest expression in pericytes among cells of the
NVU. Igf2 mRNA expression level was 487.25 times
higher in pericytes than in endothelial cells, and 86.62
times more in pericytes vs. astrocytes in the mouse
brain (Fig. S3B). In our human and mouse pericytes,
not only Igf2, but Igf1 mRNA was also expressed
(Fig. 5A,B). More Igf2 than Igf1 mRNA was found
both in human and mouse pericytes; however, the
ratio was higher in human cells. Mouse astrocytes
expressed very low amounts of Igf1 and Igf2 mRNA,
while in HAs both Igf1 and Igf2 mRNA levels were
higher than in tumor cells, but still lower than in peri-
cytes.
These data were confirmed on the protein level using
ELISA. Human pericytes secreted more than
1000 pgmL1 IGF2 corresponding to almost 100 pg/
100 000 cells, while in astrocytes we detected signifi-
cantly less IGF2 (< 200 pgmL1, < 40 pg/100 000
cells) (Fig. 5C). IGF1 levels in both pericyte- and
astrocyte-conditioned media were below the detection
limit of 1.95 ngmL1. By using immunofluorescence,
we found both IGF1 and IGF2 to be expressed in
CD13-positive pericytes in the human brain (Fig. S3C,
D). IGF1 was also detected in a few CD13-negative
cells, probably astrocyte end-feet, while IGF2 was
mainly expressed in pericytes. In human TNBC brain
metastatic lesions, the expression of IGF1 and IGF2
was highly restricted to perivascular cells (Fig. 5D,E).
3.5. Role of brain pericyte-secreted IGFs in
proliferation of TNBC cells
By binding to the type 1 insulin-like growth factor
receptor (IGF1R), IGFs are involved in growth and
survival of both normal and neoplastic cells [24].
Therefore, we next tested whether pericyte-secreted
IGFs are responsible for the increased proliferation
rate of breast cancer cells. For this purpose, we used a
selective inhibitor of IGF1R, PPP, which efficiently
blocks IGF1R without inhibiting the insulin receptor,
and has low toxicity in rodents [25]. Addition of PPP
to pericyte-conditioned medium reduced its prolifera-
tion-inducing effect to almost control levels both in
human and mouse breast cancer cells (Fig. 6A,B).
In addition, we silenced Igf2 gene in pericytes, col-
lected conditioned media, and performed a prolifera-
tion assay (Fig. 6C). Igf2 silencing was very efficient,
and although slightly affected Igf1 mRNA expression
as well (Fig. 6D), it can be considered specific, due to
the much higher expression of IGF2 compared to
IGF1 in brain pericytes (Fig. 5). Proliferation rate of
breast cancer cells in conditioned media of Igf2-si-
lenced pericytes was similar to control cells, or cells
cultured in pericyte-conditioned media in the presence
of PPP (Fig. 6C).
In line with secreted IGF2 levels, astrocyte-condi-
tioned media had a much less pronounced effect on
proliferation of breast cancer cells and no effect on
melanoma cell division. PPP reversed the astrocyte-
conditioned medium-induced slight increase in breast
cancer cell proliferation (Fig. S4A,B).
In contrast to breast cancer cells, proliferation of
melanoma cells was not affected by PPP (Fig. S4C). In
order to understand the discrepancy between the effect
of pericyte-derived IGFs on breast cancer and mela-
noma cells, we analyzed receptor expression level of
the two cell types. Igf1R mRNA expression level was
similar in the two cell types; however, melanoma cells
expressed almost two times more Igf2R mRNA than
breast cancer cells (Fig. 6E). This is in line with data
from the Human Protein Atlas (https://www.proteina
tlas.org/ENSG00000197081-IGF2R/pathology), which
indicates a higher average mRNA and protein expres-
sion of IGF2R in melanoma than in breast cancer.
This might partly explain the resistance of melanoma
cells to IGFs, because IGF2R directs IGF2 to lyso-
somes to attenuate signaling [26].
Since PPP can cross the BBB [27], we next designed
an in vivo setup to test the role of IGFs in breast
Fig. 3. Role of pericyte-secreted factors in tumor cell adhesion. (A) Representative phase-contrast images of human breast cancer or
melanoma cells (MDA or A2058, respectively) attached to noncoated cell culture dishes in control or pericyte-conditioned media after
120 min (MDA) or 20 min (A2058). Scale bar = 100 µm. (B) Quantification of adhesion results shown in (A). N = 5, average  SD,
**P < 0.01 (ANOVA and Bonferroni’s post hoc test). (C) Representative phase-contrast images of mouse breast cancer or melanoma cell
adhesion (4T1 and B16 cells, respectively) 20 min after plating. Scale bar = 100 µm. (D) Quantification of adhesion results shown in (C).
N = 5, average  SD, **P < 0.01 (ANOVA and Bonferroni’s post hoc test). Insets in (A) and (C) show cells having typical round and
elongated morphology (upper and bottom panels, respectively) (2.5 times of magnification compared to whole pictures). (E) Adhesion of
MDA and A2058 cells in culture dishes pretreated for 24 h with conditioned media of D3, HBVP, or HA cells. N = 3, average  SD,
**P < 0.01 (all cells), ##P < 0.01 (elongated cells). Breast cancer cells: significant difference among all groups (ANOVA and Bonferroni’s
post hoc test). (F) Secretion of collagen type IV and fibronectin into culture media of brain and tumor cells (representative western blot
images). (G) Quantification of collagen type IV and fibronectin western blots. N = 3, average  SD (statistically not analyzed).
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cancer brain metastasis development. In order to test
metastatic cell proliferation in the brain parenchyma,
PPP was administered on days 5 and 6 after inocula-
tion of tumor cells (Fig. 7A), when majority of cells
have completed extravasation from cerebral capillaries
[16]. Our results clearly showed that PPP inhibited
proliferation of breast cancer cells in the brains of
mice (Fig. 7B,C). The brain area covered by tumor
cells became significantly, more than 2.5 times smaller
in animals treated with the IGF1R inhibitor (Fig. 7D).
4. Discussion
Implicated in extravasation of malignant cells through
the BBB and influencing their ability to survive and
proliferate in the cerebral environment, cells of the
NVU have been increasingly recognized as key players
in brain metastasis formation. Although interactions
between metastatic cells and CECs, astrocytes, or
microglia are relatively well characterized [6], our
knowledge about the role of pericytes is restricted to
indirect effects on tumor cells, including regulation of
blood–tumor barrier permeability [28] and secretion of
connective tissue proteins [21]. By remodeling the
perivascular niche [29], increasing angiogenesis [29],
and acquiring an immunosuppressive function [31,32],
pericytes have undisputed roles in promoting primary
brain tumors. Therefore, we hypothesized that peri-
cytes might facilitate progression of brain metastases
as well.
By using in vivo and in vitro techniques and human
samples, here we show and characterize direct interac-
tions of brain pericytes with metastatic cells. First,
others [20] and we have observed that pericytes remain
attached to the vessels and are retained in metastatic
lesions, while astrocytes are expelled to the border of
the tumor [16]. In addition, inside the tumor mass, we
found PDGFRb and CD13 double-positive, non-
perivascular pericyte-like cells, origin of which is
unknown. Second, we proved direct interaction
between tumor cells and pericytes in vitro as well, by
showing that breast cancer cells preferentially attach to
pericytes, avoiding free culture surfaces.
Our results point to a pronounced role of pericyte-
secreted soluble factors, having chemoattractant, adhe-
sion- and proliferation-enhancing effects mainly on tri-
ple-negative mammary carcinoma cells. We observed
that pericytes secrete proteins of the extracellular
matrix to enhance formation of tumor cell focal adhe-
sions. In the brain, interaction with the vascular base-
ment membrane is critical for the survival of
metastatic cells [33,34]. Embedded in the inner,
endothelial layer of the vascular basal lamina, peri-
cytes substantially contribute to the secretion of matrix
proteins [35], which might be particularly important in
metastatic tumors, which tend to detach astrocytes—
another major source of basal membrane proteins—
from co-opted vessels. This is in line with accumula-
tion of collagen secreted by perivascular cells observed
in papillary-type human brain metastases [21].
Besides enhancing adhesion to the substrate, peri-
cytes inhibit intercellular adhesions and expression of
E-cadherin, conferring breast cancer cells a migratory,
invasive phenotype, characteristic of cells undergoing
epithelial-to-mesenchymal transition (EMT) [36]. In
line with these results, pericytes have been shown to be
Fig. 4. Role of pericyte-secreted factors in tumor cell proliferation. (A, B) Representative phase-contrast images of tumor cells grown in
control or pericyte-conditioned medium for 4 days. Scale bars = 100 µm. (C) Cyclin D1 expression in tumor cells grown in control or
pericyte-conditioned medium for 4 days. (D) Quantification of cyclin D1 western blots. N = 3, average  SD, **P < 0.01 (ANOVA and
Bonferroni’s post hoc test). (E) Quantification of cell numbers of MDA cells grown in control, pericyte-conditioned, and EV-depleted media.
N = 4, average  SD, **P < 0.01 (ANOVA and Bonferroni’s post hoc test). (F) Representative high-magnification phase-contrast images of
MDA cells grown in control or pericyte-conditioned medium for 4 days. Scale bar = 100 µm. (G) E-cadherin expression in MDA cells grown
in control or pericyte-conditioned medium for 4 days. (H) Quantification of E-cadherin western blots. N = 3, average  SD, **P < 0.01
(Student’s t-test).
Fig. 5. Insulin-like growth factor expression in pericytes. (A, B) Igf1 and Igf2 mRNA expression in human and mouse brain and tumor cells,
as assessed by qPCR with GAPDH as housekeeping gene. Results are shown as fold change in comparison with Igf1 in pericytes. Inset in
(A) shows human Igf1 expression in a lower scale range. N = 3, average  SD (statistically not analyzed). (C) IGF2 secretion in human brain
pericytes and astrocytes, as assessed by ELISA. N = 3 pericytes, N = 2 astrocytes, average  SD, *P < 0.05, **P < 0.01 (Student’s t-test).
(D) Representative immunofluorescence staining showing co-localization of IGF1 and CD13 in human TNBC brain metastatic tissue. Scale
bar = 10 µm. (E) Representative immunofluorescence staining showing co-localization of IGF2 and CD13 in human TNBC brain metastatic
tissue. Scale bar = 10 µm.
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Fig. 6. Role of IGFs in breast cancer cell proliferation in vitro. (A) Quantification of MDA cell growth in control or pericyte-conditioned media
in the presence or absence of PPP. Cells were counted in phase-contrast micrographs. N = 5, average  SD, *P < 0.05 (ANOVA and
Bonferroni’s post hoc test). (B) Growth of 4T1 cells in control or pericyte-conditioned media in the presence or absence of PPP, as
assessed by impedance measurements. N = 4, average  SD, P < 0.001 (cells cultured in pericyte-conditioned media compared to control),
P < 0.05 (cells treated with PPP compared to control; cells cultured in pericyte-conditioned media and PPP compared to cells cultured in
pericyte-conditioned media) (two-way ANOVA with repeated measures and Tukey’s post hoc test). (C) Growth of MDA cells cultured in
control or pericyte-conditioned media in the presence or absence of PPP, or in conditioned media of Lipofectamine-treated or Igf2-silenced
pericytes. N = 5, average  SD, **P < 0.01 (compared to control), ##P < 0.01 (compared to cells cultured in pericyte-conditioned media)
(ANOVA and Bonferroni’s post hoc test). (D) Effect of Igf2 silencing on Igf2 and Igf1 mRNA expression in HBVP cells, as assessed by qPCR
with GAPDH as housekeeping gene. N = 3, average  SD, P < 0.05 (ANOVA and Bonferroni’s post hoc test). (E) Igf1R and Igf2R mRNA
expression in human tumor cells. Results are shown as fold change in comparison with Igf1R in breast cancer cells. N = 3, average  SD,
*P < 0.05 (ANOVA and Bonferroni’s post hoc test).
2053Molecular Oncology 14 (2020) 2040–2057 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
K. Molnar et al. Pericytes promote brain metastasis formation
major sources of EMT factors in glioma [37]. We have
also found that pericytes have a prompt effect on the
proliferation of TNBC, but not of melanoma cells.
Bioinformatics analysis, followed by experimental
approaches confirmed high expression of IGFs in peri-
cytes, contributing to breast cancer cell proliferation
in vitro and in vivo. Indeed, in addition to regulating
cell division, the IGF system has also been shown to
promote induction of the EMT phenotype in epithelial
tumors [38,39] and to play an important role in the
maintenance of cancer stem cells in breast cancer [40].
Insulin-like growth factor signaling has been impli-
cated in the growth and survival of both normal and
malignant cells. IGF1R expression and activity
increase in several tumor types, including breast cancer
[41], resulting in enhanced proliferation rate, meta-
static capacity, and resistance to chemotherapy [42].
Therefore, targeting of the IGF axis has been in the
focus of therapeutic approach developments in numer-
ous malignant diseases [43]. However, since many clini-
cal trials have failed and further studies have been
discontinued due to toxicity or low efficacy of the
tested compounds, identification of predictive
biomarkers is urged to define potentially responsive
patient subgroups. Nevertheless, brain metastatic dis-
ease has not been specifically investigated in IGF1-tar-
geting clinical trials, although inhibition of IGF1R has
been shown to reduce breast cancer brain metastasis
development in experimental models [44]. Moreover, a
clinical phase I study has been completed with PPP
(AXL1717) in patients with primary brain tumors,
showing that the drug was well tolerated and no major
side effects occurred [45].
5. Conclusions
Taken together, our results show that pericytes play
crucial role in the development of brain secondary
tumors by directly influencing key steps of metastatic
colonization of the CNS. Secretion of soluble factors,
including extracellular matrix proteins and growth fac-
tors, endows brain pericytes with significant pro-meta-
static features, especially in breast cancer. Therefore,
influencing pericyte functions might represent a future
Fig. 7. Role of IGFs in breast cancer cell proliferation in vivo. (A) Experimental design of studying the role of IGFs in TNBC proliferation in
the brains of mice. (B, C) Representative confocal micrographs of parietal brain sections of control FVB/Ant:TgCAG-yfp mice and animals
treated with PPP, 8 days after inoculation of 4T1-tdTomato cells. Red channel represents tumor cells (B). In (C), the same sections are
shown as in (B) in three channels: red, green (endothelium), and blue (nuclei) channels. Scale bar = 100 µm. (D) Quantification of tumor size
in control and PPP-treated mice. Tumor area is presented as percentage of brain area, as calculated from 17 brain sections of three animals/
treatment. Average  SEM, **P < 0.01 (two-way ANOVA without replication).
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therapeutic opportunity in brain metastatic disease.
This is in line with emerging approaches, which tend
to target the more stable tumor microenvironment in
addition to the very plastic cancer cells. Moreover,
our study underlines the importance of IGF axis inhi-
bition as a potential strategy in brain metastases, espe-
cially as there exists a compound (PPP/AXL1717)
with high selectivity on IGF1R that not only has low
toxicity, but is also BBB permeable. This is a great
advantage, since the BBB represents the highest obsta-
cle in the development of drugs targeting the CNS
[46].
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